Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC
/ Antonio Passaro / Jan Andreasen
New Treatment Possibilities Improve Future Outcomes of Lung Cancer
/ BestPractice Nordic
No Major Breakthroughs in Lung Cancer Compared to ESMO 2023
/ BestPractice Nordic
Høydepunkter fra ESMO 2024 om lungekreft
/ Bjørn Henning Grønberg